Barraquer Eye Hospital UAE Expands Advanced Treatment Options for Thyroid Eye Disease with TEPEZZA

28/08/2026

Dubai, UAE – August 2026 – Barraquer Eye Hospital UAE is strengthening its commitment to advanced ophthalmic care by becoming one of the first eye hospitals in the UAE to offer TEPEZZA (teprotumumab) to patients living with Thyroid Eye Disease (TED).

Thyroid Eye Disease is a complex autoimmune condition affecting the tissues and muscles around the eyes and is often associated with thyroid disorders. Symptoms may include eye bulging (proptosis), double vision, redness, swelling, dryness, pain, pressure and eyelid retraction. In advanced cases, TED can significantly affect vision and quality of life.

TEPEZZA is a targeted therapy developed specifically for Thyroid Eye Disease. It targets insulin-like growth factor-1 receptor (IGF-1R), a key pathway involved in the disease process. TEPEZZA has been studied in patients with TED and has demonstrated improvements in key manifestations, including eye bulging and double vision, as well as other symptoms associated with the condition.

"Thyroid Eye Disease can have a profound impact on a patient's vision, comfort, appearance and overall quality of life. Having access to targeted treatment options such as TEPEZZA allows us to further personalize care according to each patient's condition and clinical needs."

TED can present differently from one patient to another. Early assessment by an ophthalmologist with experience in TED is important to determine disease activity and identify the most appropriate treatment pathway. Treatment decisions should be made following a comprehensive medical assessment and discussion with the treating specialist.

With the availability of TEPEZZA, Barraquer Eye Hospital UAE continues to expand access to specialized treatments for complex eye conditions within the UAE.